Zynex, Inc. is a medical technology company specialized in the manufacturing and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring. The Companyâ€™s devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Companyâ€™s products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave, M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Private Labeled Rehabilitation Products, which include Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces, Bracing (Knee and Wrist), and Dynacomp, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

Market Cap	3.83M 3.3M 3.04M 2.85M 5.36M 362M 5.41M 35.91M 13.99M 177M 14.37M 14.06M 614M	P/E 2023	40.3x	P/E 2024	89x
Enterprise Value	38.02M 32.77M 30.17M 28.33M 53.19M 3.59B 53.75M 357M 139M 1.76B 143M 140M 6.1B	EV / Sales 2023	2.17x	EV / Sales 2024	1.5x
Free-Float	38.37%	Yield 2023 *	-	Yield 2024	-

03-26	Altivera Medical Holdings, LLC acquired Zynex, Inc.	CI
03-26	Zynex, Inc. Secures Term Loan Credit Agreement Finalized	CI
03-26	Zynex, Inc. Emerged from Bankruptcy	CI
03-20	Court confirms Zynex plan of reorganization on March 19, 2026 - SEC filing	RE
03-19	Third Amended Reorganization Plan Approved for Zynex, Inc.	CI
02-19	Zynex Inc says SEC concluded investigation into Zynex, no enforcement action planned	RE
02-17	Zynex Inc resolves federal investigation into business practices	RE
02-10	Notice of Auction Cancellation and Designation of Successful Bidder Filed by Zynex, Inc.	CI
02-07	Third Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Zynex, Inc.	CI
02-04	Zynex, Inc. Announces New In-Network Provider Status with Humana	CI
02-02	Second Amended Joint Disclosure Statement Conditionally Approved and Combined Hearing of Second Amended Disclosure Statement and Reorganization Plan Approved for Zynex, Inc.	CI
02-01	Second Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Zynex, Inc.	CI
01-29	First Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Zynex, Inc.	CI

01/08/25	RBC Capital Adjusts Price Target on Zynex to $2 From $3, Maintains Sector Perform Rating	MT
01/08/25	HC Wainwright Downgrades Zynex to Neutral From Buy	MT
31/07/25	Medtech Zynex's Q2 revenue falls more than expected, names new CEO, suspends forecast	RE
15/07/25	RBC Cuts Price Target on Zynex to $3 From $4, Keeps Sector Perform Rating	MT
30/04/25	RBC Cuts Price Target on Zynex to $4 From $5, Keeps Sector Perform Rating	MT

03-27	ZYXIQ Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026	NE
03-26	ZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements	PR
03-26	ZYXIQ SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026	NE
03-25	Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Zynex, Inc. Lawsuit - ZYXIQ	PR
03-24	ZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements	PR

27/12/22	Top 50 Small-caps 2023
21/12/22	Top 50 Small-caps 2023
21/10/21	Los valores del Nasdaq con mayor crecimiento
21/10/21	Les actions du Nasdaq avec la plus forte croissance

Zynex Inc. Share Price Other OTC

Stocks

US98986M1036

Advanced Medical Equipment & Technology

Valuation: Zynex Inc.

Latest news : Zynex Inc.

Last Transcript: Zynex Inc.

Analysts' recommendations: Zynex Inc.

Press Releases: Zynex Inc.

News in other languages: Zynex Inc.

Quotes and Performance

Managers and Directors: Zynex Inc.

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Manager	Title	Age	Since
Steven Dyson CEO	Chief Executive Officer	53	17/08/2025
Vikram Bajaj DFI	Director of Finance/CFO	50	17/08/2025
John Bibb LAW	General Counsel	53	17/08/2025

Director	Title	Age	Since
Vikram Bajaj BRD	Director/Board Member	50	25/03/2026
John Bibb BRD	Director/Board Member	53	25/03/2026

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ZYNEX INC.	+1.63%	+29.33%	-	-	1.69M
THERMO FISHER SCIENTIFIC, INC.	-0.46%	-2.27%	+20.71%	-10.68%	176B
INTUITIVE SURGICAL, INC.	-0.75%	+0.73%	-18.96%	+26.60%	148B
DANAHER CORPORATION	-0.47%	-1.64%	-7.73%	-23.66%	128B
BOSTON SCIENTIFIC CORPORATION	-1.69%	-4.39%	-54.57%	-14.47%	69.74B
EDWARDS LIFESCIENCES CORPORATION	+0.25%	+3.44%	+21.38%	-3.24%	51B
SIEMENS HEALTHINEERS AG	-1.84%	-1.28%	-24.46%	-33.85%	45.7B
AGILENT TECHNOLOGIES, INC.	-1.19%	-3.36%	+9.57%	+7.65%	36.25B
WATERS CORPORATION	+0.31%	-0.24%	+6.22%	+37.62%	35.4B
GE HEALTHCARE TECHNOLOGIES INC.	-0.62%	-1.40%	-11.62%	-20.32%	28.76B
Average	-0.43%	-2.78%	-6.61%	-3.82%	79.84B
Weighted average by Cap.	-0.65%	-3.05%	-5.23%	-3.73%

	2023	2024
Net sales	184M 159M 146M 137M 258M 17.43B 261M 1.73B 673M 8.53B 692M 677M 29.57B	192M 166M 153M 143M 269M 18.19B 272M 1.8B 703M 8.91B 722M 707M 30.86B
Net income	9.73M 8.39M 7.72M 7.25M 13.61M 920M 13.76M 91.26M 35.55M 451M 36.52M 35.75M 1.56B	2.99M 2.58M 2.38M 2.23M 4.19M 283M 4.23M 28.08M 10.94M 139M 11.24M 11M 480M
Net Debt	31.59M 27.22M 25.07M 23.54M 44.19M 2.99B 44.66M 296M 115M 1.46B 119M 116M 5.07B	34.19M 29.47M 27.13M 25.48M 47.83M 3.23B 48.34M 321M 125M 1.58B 128M 126M 5.49B